Michael S. Glickman, MD
Professor
Research Focus
Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.Education
MD, Columbia University College of Physicians and Surgeons- Office Phone: 646-888-2368
- Office Fax: 646-422-0502
- Lab Phone: 646-888-2360
- Lab Fax: 646-422-0502
Lab Members
Member
Research Scholar
Research Scholar
Assistant member L1
Graduate Student
Graduate Student
TBRU Data Coordinator
Senior Research Technician
Postdoctoral Fellow
Research Technician
ID fellow
Postdoctoral Fellow
Publications
- Wipperman MF, Heaton BE, Nautiyal A, Adefisayo O, Evans H, Gupta R, van Ditmarsch D, Soni R, Hendrickson R, Johnson J, Krogan N, Glickman MS. Mycobacterial Mutagenesis and Drug Resistance Are Controlled by Phosphorylation- and Cardiolipin-Mediated Inhibition of the RecA Coprotease. Mol Cell. 2018 Aug 22. pii: S1097-2765(18)30606-3. doi: 10.1016/j.molcel.2018.07.037. [Epub ahead of print] PubMed
- Redelman-Sidi, G., Iyer, G., Solit, D., and Glickman, M.S. Oncogenic activation of Pak1 dependent Macropinocytosis pathway determines BCG entry into bladder cancer cells. Cancer Res. 2013 Feb 1;73(3):1156-67.
